Voorbeelden van het gebruik van Arzerra in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Arzerra contains sodium.
Vaccination and Arzerra.
How is Arzerra used?
Before diluting Arzerra.
How has Arzerra been studied?
Other information about Arzerra.
Why has Arzerra been approved?
Hepatitis B(a liver disease) before starting Arzerra treatment.
What is Arzerra used for?
Arzerra and Chlorambucil N=221.
What benefit has Arzerra shown during the studies?
Arzerra is given using an infusion pump.
Your doctor will weigh up the benefit to you against the risk to your baby of taking Arzerra while you're pregnant.
Arzerra is available in 1-vial packs.
Patients should always be pre-medicated 30 minutes to 2 hours prior to Arzerra infusion according to the following dosing schedules.
Arzerra is available in packs of 3 vials.
Insufficient data exist regarding the safety of resuming Arzerra in patients who develop HBV reactivation.
What Arzerra looks like and contents of the pack?
In patients who develop reactivation of HBV while receiving Arzerra, Arzerra and any concomitant chemotherapy should be interrupted immediately, and appropriate treatment instituted.
Arzerra 1,000 mg concentrate for solution for infusion.
Do not use the Arzerra concentrate if there is discolouration.
Arzerra is used to treat chronic lymphocytic leukaemia CLL.
The PFS in the monotherapy Arzerra arm was comparable to the results seen with Arzerra monotherapy in study Hx-CD20-406.
Arzerra is not usually recommended for use during pregnancy.
The results of this study demonstrated that Arzerra in combination with bendamustine is an effective therapy providing an ORR of 95%(95% CI:
Arzerra is a colourless to pale yellow concentrate for solution for infusion.
Resumption of Arzerra in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B.
Arzerra should be discontinued in patients who experience serious
Arzerra treatment should not be initiated in patients with evidence of current hepatitis B infection(HBsAg positive) until the infection has been adequately treated.